Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human adaptive study of oral GM-1020 in healthy volunteers
NL-OMON53597Phase 1Active, not recruiting
- Sponsor
- Gilgamesh Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of blixeprodil in major depressive disorder (MDD) (5 arms), sponsored by Gilgamesh Pharmaceuticals. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Nov 2022; status: active, not recruiting.
02
Drugs
blixeprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON53597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53597.